By Ludwig Burger FRANKFURT (Reuters) – Germany’s BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, its CEO Ugur Sahin said, adding that despite the mutation shots should continue to protect people against severe disease. BioNTech and Pfizer Inc together produced one of the first vaccines against COVID-19, with well over 2 billion doses already given to protect people around the world. There are concerns that the vaccines might not work as well against the Omicron variant which emerged last month. “This variant might be able to infec…

Read More